Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Urologic Neoplasms × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 32 Neoplasms 8 Breast Neoplasms 8 Head and Neck Neoplasms 4 Lung Neoplasms 3 Carcinoma, Squamous Cell 3 Adenocarcinoma 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thoracic Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Squamous Cell Cancers of the Head and Neck 1 Rhabdomyosarcoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Pleural Neoplasms 1 Pleural Effusion, Malignant 1 Pleural Effusion 1 Pleural Diseases 1 Neuroectodermal Tumors 1 Neoplasms by Site 1 Multiple Myeloma 1 Lymphoma 1 Lung Diseases 1

Interventions

Trastuzumab 2 valrubicin 1 niraparib 1 enfortumab vedotin 1 avelumab 1 Surveys and Questionnaires 1 Sunitinib 1 Sugammadex 1 Standard of Care 1 Paclitaxel 1 Neostigmine 1 Neoadjuvant Therapy 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Cetuximab 1 Afatinib 1 Administration, Intravesical 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡